First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

Phase 2

Terminated

Conditions: Bladder Carcinoma
Transitional Cell Carcinoma
Urothelial Carcinoma

Interventions: Drug: Everolimus
Drug: Paclitaxel

Registration Number: NCT01215136

Lead Sponsor: Matthew Galsky

Brief Summary: The purpose of this trial is to explore the activity and safety of everolimus +/- paclitaxel as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma.

Detailed Description: OUTLINE: This is a multi-center study

Patients will be enrolled into one of two parallel cohorts:

* Cohort 1: impaired renal function AND poor performance status (cycle length = 28 days). Everolimus 10 mg orally daily

* Cohort 2: impaired renal function OR poor performance status (cycle length = 28 days). Everolimus 10 mg orally daily + IV Paclitaxel 80 mg/m2 on D1, 8, 15

Restaging evaluations will be performed after every 2 cycles.

Treatment will continue until disease progression or unacceptable toxicity.

Karnofsky performance status 60-70%

Life Expectancy: Not specified

Hematopoietic:

* Absolute neutrophil count (ANC) ≥ 1.5 K/mm3

* Hemoglobin (Hgb) ≥ 9 g/dL

* Platelets ≥ 100 K/mm3

* INR ≤ 1.5 (Anticoagulants are allowed if target INR ≤ 1.5 on a stable dose of warfarin or on a stable dose of Low molecular weight (LMW) heparin for at least 2 weeks prior to registration for protocol therapy).

* Fasting serum cholesterol ≤300 mg/dL OR ≤7.75 mmol/L

* Fasting triglycerides ≤ 2.5 x ULN.

* Fasting serum glucose \< 1.5 x ULN

Hepatic:

* Bilirubin ≤ 1.5 x ULN

* Aminotransferases (AST and ALT) ≤ 2.5 x ULN (unless liver metastases, then ≤ 5 x ULN)

Renal:

* Calculated creatinine clearance of \< 60 using the Cockcroft-Gault formula

Cardiovascular:

* No symptomatic congestive heart failure of New York heart Association Class III or IV.

* No unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease.

Recruitment & Eligibility

Status: TERMINATED

Sex: All

Target Recruitment: 36

Inclusion Criteria

Histological or cytological proof of transitional cell carcinoma (TCC) of the bladder, urethra, ureter, or renal pelvis (urothelial carcinoma). Histology may be mixed, but still requires a component of TCC.
Measurable disease according to RECIST and obtained by imaging within 30 days prior to registration for protocol therapy.
Must be ineligible for cisplatin, based on the following, within 30 days prior to registration for protocol therapy.
Prior radiation therapy is allowed to < 25% of the bone marrow.
Written informed consent and HIPAA authorization for release of personal health information.
Age > 18 years at the time of consent.
Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control; abstinence) from the time consent is signed until 8 weeks after treatment discontinuation.
Females of childbearing potential must have a negative pregnancy test within 7 days prior to prior to registration for protocol therapy.
Females must not be breastfeeding.

Exclusion Criteria

No prior chemotherapy for metastatic disease. Prior chemotherapy in the neoadjuvant/adjuvant setting is allowed if completed at least 12 months prior to registration for protocol therapy.
No active CNS metastases or leptomeningeal metastases. Patients with neurological symptoms must undergo a head CT scan or brain MRI to exclude brain metastasis.
No prior malignancy is allowed except for adequately treated basal cell or adequately treated squamous cell skin cancer, in situ cervical cancer, Gleason ≤ grade 7 prostate cancers (treated definitively with no evidence of PSA progression), or other cancer for which the patient has been disease-free for at least 5 years.
No treatment with any anticancer therapy or investigational agent within 30 days prior to registration for protocol therapy.
No known hypersensitivity to any protocol treatment.
No prior treatment with mTOR inhibitor (sirolimus, temsirolimus, everolimus).
No history of immunization with attenuated live vaccines within one week prior to registration for protocol therapy or during study period.
No severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air.
No uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN.
No active (acute or chronic) or uncontrolled severe infections.
No liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis.
No known history of HIV seropositivity.
No impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of everolimus (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection).
No active, bleeding diathesis.
No history of major surgery (defined as requiring general anesthesia) or significant traumatic injury within 30 days prior to registration for protocol therapy.

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cohort 1	Everolimus	Single-agent everolimus (enrollment limited to patients with patients with creatinine clearance \< 60 ml/min AND Karnofsky performance status of 60-70%)
Cohort 2	Paclitaxel	Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance \< 60 ml/min OR Karnofsky performance status of 60-70%)
Cohort 2	Everolimus	Everolimus plus paclitaxel (enrollment limited to patients with creatinine clearance \< 60 ml/min OR Karnofsky performance status of 60-70%)

Primary Outcome Measures

Name	Time	Method
Response Rate of Single-Agent Everolimus and Everolimus + Paclitaxel	4 months	To evaluate clinical benefit rate (complete response, partial response, and stable disease) at 4 months from initiation of treatment.

Secondary Outcome Measures

Name	Time	Method
Number of Adverse Events as a Measure of Safety and Tolerability	5 months	To determine the safety of everolimus and everolimus plus paclitaxel in this patient population. A summary with the count of events per grade is provided.
Progression Free Survival	4 months	To determine median progression free survival per RECIST 1.1, per cohort.
Overall Survival	12 months	To determine median overall survival at 1-year from the initiation of treatment.

Trial Locations

Locations (11): Cancer Care Center of Southern Indiana
🇺🇸
Bloomington, Indiana, United States
Metro Health Cancer Care
🇺🇸
Wyoming, Michigan, United States
Icahn School of Medicine: Tisch Cancer Institute at Mount Sinai Medical Center
🇺🇸
New York, New York, United States
Virginia Oncology Associates
🇺🇸
Norfolk, Virginia, United States
University of Alabama Hematology Oncology Clinic at Medical West
🇺🇸
Birmingham, Alabama, United States
IU Health Central Indiana Cancer Centers
🇺🇸
Indianapolis, Indiana, United States
Northwestern University, Robert H. Lurie Comprehensive Cancer Center
🇺🇸
Chicago, Illinois, United States
Nebraska Cancer Specialists
🇺🇸
Omaha, Nebraska, United States
University of Texas Medical Branch
🇺🇸
Galveston, Texas, United States
Indiana University Melvin and Bren Simon Cancer Center
🇺🇸
Indianapolis, Indiana, United States
MUSC Hollings Cancer Center
🇺🇸
Charleston, South Carolina, United States